<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03795389</url>
  </required_header>
  <id_info>
    <org_study_id>DM199-2018-001</org_study_id>
    <nct_id>NCT03795389</nct_id>
  </id_info>
  <brief_title>A Study to Asses Pharmacokinetics, Safety, and Tolerability of DM199 in Patients With Diabetes Mellitus and Chronic Kidney Disease</brief_title>
  <official_title>A Multi-Center Open-label Investigation to Assess the Pharmacokinetics, Safety and Tolerability of DM199 in Patients With Diabetes Mellitus and Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DiaMedica Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DiaMedica Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, phase IB, multi-center study evaluating DM199 in subjects with Type 1 Diabetes
      or Type 2 Diabetes and Stage 3 or 4 Chronic Kidney Disease. The primary objectives of this
      study are to evaluate safety, tolerability, and PK profile of DM199 in these subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2019</start_date>
  <completion_date type="Actual">July 21, 2019</completion_date>
  <primary_completion_date type="Actual">July 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by incidence, severity, and causality of adverse events</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability as assessed by incidence and severity of AEs</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma measurements of DM199</measure>
    <time_frame>11 days</time_frame>
    <description>as measured in the three different dosing groups; 3.0 ug/kg, 5.0 ug/kg, and 8.0 ug/kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DM199 urine concentrations of KLK1</measure>
    <time_frame>11 days</time_frame>
    <description>urine KLK1 will be measured pre and post study drug administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C Reactive protein (CRP)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matrix Metalloproteinase-9 (MMP-9)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Endothelial Growth Factor (VEGF)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitric Oxide (NO)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutrophil gelatinase-associated prostaglandin E2</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Kidney Injury Molecule-1 (Kim1)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>serum creatinine</measure>
    <time_frame>11 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood glucose</measure>
    <time_frame>11 days</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Chronic Kidney Disease, Stage 3 (Moderate)</condition>
  <condition>Chronic Kidney Disease, Stage 4 (Severe)</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>3.0 µg/kg SC, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=8, study group of T1D or T2D with stage 3 CKD. separate n=8 of study group with T1D or T2D with CKD stage 4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.0 µg/kg SC, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=8, study group of T1D or T2D with stage 3 CKD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8.0 µg/kg SC, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=8, study group of T1D or T2D with stage 3 CKD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DM199</intervention_name>
    <description>Single SC dose</description>
    <arm_group_label>3.0 µg/kg SC, single dose</arm_group_label>
    <arm_group_label>5.0 µg/kg SC, single dose</arm_group_label>
    <arm_group_label>8.0 µg/kg SC, single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is willing and able to provide informed consent for study participation.

          -  Subject is ≥ 18 years of age.

          -  Subject has an established diagnosis of T1D or T2D as determined by medical evaluation
             at screen.

          -  Subjects A1c &lt;9.8%

          -  Subject is clinically stable with respect to underlying renal impairment and diabetes,
             as assessed by the Investigator's medical evaluation.

          -  Subject has been diagnosed with Stage 3 CKD as defined by eGFR (MDRD) between 30 - &lt;60
             or Stage 4 as defined by eGFR &lt;30 (not on dialysis) at screening.

          -  Subject has a body mass index (BMI) between 18 to 45 kg/m2 (inclusive).

        Exclusion Criteria:

          -  Subject has positive drug test for drugs of abuse and/or positive alcohol breath test
             at screening and Day 0.

          -  Subject is unable or unwilling to comply with protocol requirements, including
             assessments, tests, and follow-up visits.

          -  Subject has a history of significant allergic diathesis such as urticaria, angioedema,
             or anaphylaxis.

          -  Subject has had any live vaccination ≤ 3 months prior to enrollment or will require
             vaccination during the study.

          -  Subject must not be taking an ACEi medication for 5 half-lives prior to study drug
             administration and for 5 days post study drug administration.

          -  Subject is unwilling or unable to limit smoking to ≤ 10 cigarettes per day (or other
             products that contain nicotine limited to &lt; 200 mg of nicotine/day) during the study
             participation period.

          -  Subject has a current malignancy or active malignancy ≤ 3 years prior to enrollment
             except basal cell or squamous cell carcinoma of the skin or in situ cervical cancer
             that has undergone potentially curative therapy and ≥ six months have elapsed since
             the procedure.

          -  Subject has an active infection at the time of enrollment, and/or a history of
             clinically significant acute bacterial, viral, or fungal systemic infections that
             required systemic treatment in the last four weeks prior to enrollment.

          -  Subject has known medical history of alpha 1-antitrypsin deficiency (α1-antitrypsin
             deficiency).

          -  Subject has serological evidence of human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or anti-hepatitis C virus (Anti-HCV) at screen.

          -  Subject is pregnant or nursing or is planning a pregnancy during the study period.

          -  Subject is male or female of childbearing potential, is participating in sexual
             activity that could lead to pregnancy and is unable or unwilling to practice medically
             effective contraception during the study.

          -  Subject has received any investigational drug or device within 14 days (or 5 half
             lives, whichever is longer) prior to study drug administration on Day 1

          -  Subject has renal artery stenosis as determine at screen with medical history.

          -  Subject has hypotension as defined by systolic blood pressure ≤ 90 and diastolic blood
             pressure ≤ 60 mmHg.

          -  Subject has Proteinuria: PCR&gt;2000mg/gm (spot testing).

          -  Subject does not have adequate venous access for blood sampling.

          -  Subject has any other medical condition which, in the opinion of the Investigator,
             will make participation medically unsafe or interfere with the study results.

          -  Subject has any other clinically significant abnormalities in laboratory test results
             at screening that would, in the opinion of the Investigator, increase the subject's
             risk of participation, jeopardize complete participation in the study, or compromise
             interpretation of study data.

          -  Subject has any of the following conditions as determined by ECG or medical record:

               -  Any significant arrhythmia or conduction abnormality, which, in the opinion of
                  the Investigators and Medical Monitor, may interfere with the safety of the
                  subject.

          -  Subject is taking Cimetidine, St. John's Wort, or any other herbal or probiotic
             supplement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Research</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

